Cellectis is a company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. With 15 years of expertise, Cellectis is already listed on the NYSE Alternext market (ticker: ALCLS) and now preparing its IPO to be listed on the NASDAQ.
Cellectis is considering a listing on the Nasdaq Global Market in order to increase its visibility and to access to new capital market to finance its expansion strategy. Cellectis currently expects to use the net proceeds of the issue to develop its candidate products in immuno-oncology, to continue its activities in the field of human therapeutics other than oncology, to enhance its agricultural biotechnology business, and to finance its capital working and other useful purposes.
The company intends to seek admission of its shares in the form of American Depositary Shares (ADSs) on the Nasdaq Global Market. An offer of ADSs would be conducted on this occasion by means of public offer exclusively in the United States and institutional investment in other countries. In order to realize this project, Cellectis announced the filing of a registration statement “Form F-1” (F-1). The details of the introduction to the NASDAQ can be determined only after a period of 21 days after the deposit of the F-1 and will be the subject of a separate announcement.